SHELTON, CT – NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for “Rare Pediatric Disease Drug” Designation (RPDD) for NV-387 as a Treatment for Measles with the U.S. FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.
NanoViricides will be eligible for a Priority Review Voucher (PRV) upon approval of the drug if NV-387 is designated as a Rare Pediatric Disease Drug. A PRV carries immediate economic value. It is a tradable instrument, and recently has generally fetched around $160 million upon sale of the PRV to another company [1]. A PRV carries the benefit of accelerated approval of the drug for which it is used by the purchaser, which brings this value to the PRV.
“NV-387 as an effective drug is expected to be an important tool to fight Measles resurgence in the USA and worldwide, when approved,” said Anil R. Diwan, PhD, adding, “Treating a Measles patient with NV-387 would help with rapid recovery and eliminate the high morbidity and the rare post-Measles ‘Immune Amnesia’ effects.”
“A Rare Pediatric Disease Drug Designation for NV-387 would help us tremendously in the mission of regulatory development and approval of NV-387 to treat Measles, by substantially boosting the potential economic benefits and the business case for this indication,” said Meeta R. Vyas, CFO of the Company.
There is no drug for the treatment of Measles at present.
The Rare Pediatric Disease Priority Review Voucher program was re-authorized by the US Congress and signed into Law by President Trump on February 3, 2026, as part of the Consolidated Appropriations Act of 2026 [2].
Measles cases have been rising in the USA, with 1,661 laboratory confirmed cases already reported, with occurrences across 33 states, with 17 new outbreaks, as of April 2, 2026, according to the CDC [3]. An additional 10 cases were reported to have occurred in international travelers visiting the USA. A total of 2,286 confirmed cases in 48 outbreaks were reported in 2025. The rate of hospitalization in 2026 has decreased to about 5% from the 11% rate in 2025. This decrease is presumably due to a better understanding of case handling guidelines, and the strong efforts of the CDC including updated information and toolkits for Public Health and Healthcare professionals [4].
Measles is a rare disease in the USA, with annual incidence rates well below 200,000 cases. About 70% of the cases have been in pediatric subjects (0-18 years of age), which qualifies NV-387 for Measles Treatment as a Rare Pediatric Disease Drug.
At least 8% of cases in 2026 to date, and at least 7% of cases in 2025 occurred in vaccinated individuals. The CDC reports the vaccine breakthrough rate at about 10%.
Infants below 9 months of age are not eligible for routine vaccination. Recently, at least 100 child deaths due to Measles were reported in Bangladesh during 2026, with a large portion of them in infants, leading to a vaccination campaign relaxing this lower age limit [5].
NanoViricides employed the expert services of Only Orphans Cote, LLC, (“OOC”) a regulatory consultant firm founded by Dr. Timothy Cote, for developing the RPDD application. Dr. Timothy Cote previously served as the Director of US FDA Office of Orphan Products Development (OOPD), and has intimate knowledge of the laws, rules, and regulations, governing orphan drugs, and the potential benefits to the Drug Sponsors.
There is no approved drug for the treatment of measles, although an effective vaccine exists and is generally given in a combination of 3 or 4 vaccines (MMR or MMRV) at one year of age providing lifelong immunity. Measles is a highly contagious disease. A population vaccination rate of more than 95% is thought to be needed for blocking spread of measles if a case occurs. Vaccination rates have been dropping worldwide primarily due to vaccine hesitancy.
Only an effective treatment can help the patient and can avoid the potential severe disease scenarios such as encephalitis, neurological disabilities, and potential fatalities as well as immune amnesia that can result from severe disease.
In absence of a treatment, quarantining of all contacts of a case for at least 14 days is the public health approach at present to minimize spread. Vaccination is urged for contacts but any vaccine requires 2-3 weeks from administration to become effective. Also, Measles vaccine requires 2 doses spread apart in time for full effectiveness.
Quarantining causes significant disturbances in the society, in particular, causing significant loss of in-school days for children. A preventive NV-387 treatment of contacts would eliminate the need for quarantining, with a significant positive impact for children as well as economically.
NV-387 is the only drug candidate to our knowledge that has demonstrated strong in vivo activity against lethal infection with the Measles virus in a humanized animal model study.
Measles cases are rising across the Western world including several European countries and the UK, as well as the USA and Canada. Additionally Mexico and several other Central and South American countries have also been suffering from rising Measles outbreaks. Measles is endemic in the developing and less developed nations.
Thus, a drug for Measles is sorely needed for combating Measles worldwide.
NV-387 is an unusually broad-spectrum antiviral drug that has demonstrated strong effectiveness in relevant animal models of multiple human viral infections. These include RSV, COVID, Influenza, Mpox, Smallpox, and Measles.
Over 90% of human pathogenic viruses are expected to be susceptible to NV-387, based on its design as a sulfated proteoglycan mimetic.
About Nanoviricides
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide ™ class of drug candidates and the nanoviricide ™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour ® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
Contact
NanoViricides, Inc.
[email protected]
Public Relations Contact
[email protected]
References
[3] https://www.cdc.gov/measles/data-research/index.html
[4] https://www.cdc.gov/measles/php/toolkit/index.html
[5] https://www.foxnews.com/health/least-46-children-dead-amid-measles-outbreak-virus-spreads-globally ; https://www.bbc.com/news/articles/cevkz2z7dm8o